



Press release

Stockholm, 9 July 2014

Bactiguard strengthens its sales organization by appointing Erik Düring head of European sales

Bactiguard is expanding its business, with focus on Europe, the Middle East, Asia, South America and Southern Africa. The recruitment of Erik Düring as Regional Sales Director Europe is an important step in strengthening the sales and marketing organization, which supports the company's distributors and develops the markets where Bactiguard has direct sales.

"Bactiguard is in a rapid expansion phase. We have developed our own product portfolio, which prevents hospital acquired infections, and successfully established distributors in Asia, the Middle East, South America and Southern Africa. We will now shift focus to strengthening our sales and marketing function to expand sales.

Erik Düring has solid international experience from the medtech industry. With Erik as the regional sales director for Europe, we strengthen our competence and can really start focusing on developing the Swedish and other European markets," says Johan Rugfelt CEO.

Erik Düring has a broad background in the medtech industry, including both product development and sales. He has been employed by Radi Medical Systems and St Jude Medical and, most recently, was the CEO of CMA Microdialysis AB.

Erik Düring has a Master of Science in Mechanical Engineering and will take up his new position on August 1.

For further information, please contact:

Johan Rugfelt, CEO, switchboard: +46 8 440 58 80

Cecilia Edström, Director of Communications, mobile: +46 722 262 328

About Bactiguard

Bactiguard is a Swedish medtech company with a business concept of preventing healthcare-related infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's



patented coating prevents healthcare-associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported sales of approximately SEK 130 million in 2013 and has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia. The Bactiguard share is listed on NASDAQ OMX Stockholm. Read more at www.bactiguard.se.